| Literature DB >> 35056349 |
Jung Myung Lee1, Seung Min Kathy Lee2,3, Jungtae Leem4, Jin-Bae Kim1, Jimin Park2, Jun Hyeong Park2, Suji Lee2, Hyung Oh Kim1, Hyemoon Chung1, Jong Shin Woo1, Woo-Shik Kim1, Sanghoon Lee2,5, Weon Kim1.
Abstract
Background andEntities:
Keywords: East Asian traditional; acupuncture; atrial fibrillation; flecainide; medicine; membrane transport modulator; randomized controlled trial
Mesh:
Year: 2021 PMID: 35056349 PMCID: PMC8778603 DOI: 10.3390/medicina58010041
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Figure 1Trial flow diagram of acupuncture in persistent AF. Patients received active acupuncture or sham acupuncture treatment according to the assigned sequence and AF recurrence was assessed. AF recurrence was evaluated using 48-h Holter monitoring, electrocardiography, and follow-up echocardiography. AF: Atrial fibrillation, EC: Electrical cardioversion, ECG: Electrocardiography, LA: Left atrium, LAA: Left atrial appendage.
Figure 2Location of acupuncture points. (A) PC5, PC6, HT7; (B) ST36, ST37; and (C) TF4.
Baseline characteristics and echocardiographic parameters.
| Sham Acupuncture | Acupuncture | ||
|---|---|---|---|
| Age (years) | 63.7 ± 6.5 | 69.6 ± 7.3 | 0.024 |
| Male, | 12 (80.0%) | 13 (81.2%) | 1 |
| Hypertension, | 10 (66.7%) | 14 (87.5%) | 0.339 |
| Diabetes Mellitus, | 3 (20.0%) | 2 (12.5%) | 0.937 |
| Stroke, | 0 (0.0%) | 3 (18.8%) | 0.247 |
| Vascular disease, | 0 (0.0%) | 1 (6.2%) | 1 |
| CHA2DS2VASC score | 1.6 ± 1.0 | 2.8 ± 1.5 | 0.02 |
| BSA (kg/m2) | 1.8 ± 0.2 | 1.8 ± 0.2 | 0.961 |
|
| |||
| LVEF (%) | 64.2 ± 5.3 | 61.0 ± 6.8 | 0.151 |
| LAVI (mL/m2) | 38.1 ± 7.7 | 42.2 ± 13.9 | 0.31 |
| E/E’ * | 11.5 [9.6–11.9] | 12.6 [10.4–14.7] | 0.455 |
| Medications | |||
| Beta blocker | 1 (6.7%) | 1 (6.2%) | 1.0 |
| Calcium channel blocker | 3 (20%) | 5 (31.2%) | 0.685 |
| ACEi | 0 | 2 (12.5%) | 0.484 |
| ARB | 5 (33.3%) | 8 (50%) | 0.347 |
| ACEi or ARB | 5 (33.3%) | 10 (66.6%) | 0.104 |
| Loop diuretics | 2 (13.3%) | 1 (6.2%) | 0.6 |
| Thiazide | 1 (6.7%) | 0 | 0.484 |
| Spironolactone | 2 (13.3%) | 2 (12.5%) | 1.0 |
| Any diuretics | 3 (20%) | 2 (12.5%) | 0.654 |
| Nitrate | 1 (6.7%) | 1 (6.2%) | 1.0 |
| Digitalis | 1 (6.7%) | 0 | 0.484 |
| Anticoagulant | 0.461 | ||
| Warfarin | 11 (73.3%) | 13 (81.2%) | |
| DOACs | 4 (26.7%) | 3 (18.8%) | |
| (Apixaban) | 0 | 1 (6.2%) | |
| (Dabigatran) | 3 (20%) | 1 (6.2%) | |
| (Edoxaban) | 1 (6.7%) | 0 | |
| (Rivaroxaban) | 0 | 1 (6.2%) |
Normally distributed data are expressed as mean ± standard deviation. * Non-normally distributed data are expressed as median (interquartile range). ACEi: Angiotensin-converting enzyme inhibitor, ARB: Angiotensin receptor blocker, AF: Atrial fibrillation, BSA: Body surface area, DOAC: Direct oral anticoagulants, E/E’: Mitral inflow velocity over septal mitral annulus tissue velocity, LAVI: Left atrial volume index, LVEF: Left ventricular ejection fraction, TTE: Transthoracic echocardiography, VKA: Vitamin K antagonists. Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg at more than two visits or a medical history of hypertension. Diabetes mellitus was defined as two or more of the following criteria: (1) having symptoms of diabetes (increased thirst, increased urination, and unexplained weight loss) and a blood glucose level ≥ 200 mg/dL; (2) fasting glucose level ≥ 126 mg/dL; (3) 2-h postprandial glucose ≥ 200 mg/dL by oral glucose tolerance test, hemoglobin A1C ≥ 6.5%, or a medical history of diabetes mellitus. Stroke was confirmed by previous brain computed tomography and/or magnetic resonance imaging. No newly developed stroke occurred during the study period. Vascular disease was defined as previous myocardial infarction, peripheral artery disease, or aortic plaque.
Clinical and echocardiographic outcomes three months after electrical cardioversion.
| Sham Acupuncture | Acupuncture | ||
|---|---|---|---|
| Rhythm outcomes | 0.611 | ||
| AF recurrence | 9 (60.0%) | 12 (75.0%) | |
| Sinus rhythm | 6 (40.0%) | 4 (25.0%) | |
| TTE parameters | |||
| LVEF | 63.8 ± 4.6 | 63.6 ± 5.2 | 0.903 |
| LAVI | 36.9 ± 14.1 | 36.1 ± 9.7 | 0.865 |
| E/E’ | 11.9 ± 4.5 | 11.9 ± 3.9 | 0.984 |
AF: Atrial fibrillation, E/E’: Mitral inflow velocity over septal mitral annulus tissue velocity, LAVI: Left atrial volume index, LVEF: Left ventricular ejection fraction, TTE: Transthoracic echocardiography.
Figure 3Change in left atrial size in patients of the acupuncture treatment group. * p < 0.05 compared with baseline.